Recent Updates — CLPT

ClearPoint Neuro reported third-quarter revenue of $12.1 million, a 36% increase from the prior year period, driven by a 59% surge in neurosurgery navigation and therapy sales to $5.4 million following the integration of its IRRA flow acquisition. The company also saw capital equipment and software revenue grow 68% to $1.7 million and biologics and drug delivery revenue rise 11% to $4.9 million. Operating expenses increased 23% to $13.4 million, resulting in a net loss of $7.5 million for the quarter. Management raised its full-year 2026 revenue guidance to between $48.0 million and $50.0 million from previous estimates. The company ended the quarter with $46.2 million in cash and cash equivalents.

ClearPoint Neuro, Inc. reported second quarter 2026 financial results with total revenue of $10.9 million, an 18% increase from the prior year period. Biologics and drug delivery revenue declined to $4.0 million due to lower product shipments, while neurosurgery navigation and therapy revenue rose 62% to $5.6 million driven by IRRA flow sales and new software. The company adjusted its full-year 2026 revenue guidance upward to a range of $48.0 million to $52.0 million, citing strategic investments in clinical capacity and preclinical services rather than traditional sales expansion. Operating expenses increased 51% to $17.0 million primarily due to the IRRAS acquisition. The company ended the quarter with $29.4 million in cash and cash equivalents. ClearPoint Neuro operates in the medical device industry, providing precise navigation systems for brain and spine procedures and enabling cell and gene therapy delivery.